Gemcitabine
- Generic Name
- Gemcitabine
- Brand Names
- Gemzar
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11F2N3O4
- CAS Number
- 95058-81-4
- Unique Ingredient Identifier
- B76N6SBZ8R
- Background
Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...
- Indication
Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.
In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...
- Associated Conditions
- Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
- Associated Therapies
- -
High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 29
- Registration Number
- NCT06492759
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Target Recruit Count
- 89
- Registration Number
- NCT06489808
- Locations
- 🇨🇳
Institute of Hematology & Blood Disease Hospital, Tianjin, Tianjin, China
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 34
- Registration Number
- NCT06488222
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT06483555
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
- Conditions
- Interventions
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 30
- Registration Number
- NCT06472037
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 620
- Registration Number
- NCT06467357
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06465563
- Locations
- 🇨🇳
The First Affiliated Hospital，Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT06465446
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇦🇷
Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Cordoba, Argentina
🇧🇷Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, Brazil
🇧🇷Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, Brazil
A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06457503
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.